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A B S T R A C T
Pregnane steroids, particularly allopregnanolone (AlloP), are neuroprotective in response to central insult. While
unexplored in vivo, AlloP may confer protection against the neurological dysfunction associated with human
immunodeficiency virus type 1 (HIV-1). The HIV-1 regulatory protein, trans-activator of transcription (Tat), is
neurotoxic and its expression in mice increases anxiety-like behavior; an effect that can be ameliorated by
progesterone, but not when 5α-reduction is blocked. Given that Tat's neurotoxic effects involve mitochondrial
dysfunction and can be worsened with opioid exposure, we hypothesized that Tat and/or combined morphine
would perturb steroidogenesis in mice, promoting neuronal death, and that exogenous AlloP would rescue these
effects. Like other models of neural injury, conditionally inducing HIV-1 Tat in transgenic mice significantly
increased the central synthesis of pregnenolone and progesterone's 5α-reduced metabolites, including AlloP,
while decreasing central deoxycorticosterone (independent of changes in plasma). Morphine significantly in-
creased brain and plasma concentrations of several steroids (including progesterone, deoxycorticosterone, cor-
ticosterone, and their metabolites) likely via activation of the hypothalamic-pituitary-adrenal stress axis. Tat, but
not morphine, caused glucocorticoid resistance in primary splenocytes. In neurons, Tat depolarized mitochon-
drial membrane potential and increased cell death. Physiological concentrations of AlloP (0.1, 1, or 10 nM)
reversed these effects. High-concentration AlloP (100 nM) was neurotoxic in combination with morphine. Tat
induction in transgenic mice potentiated the psychomotor effects of acute morphine, while exogenous AlloP
(1.0 mg/kg, but not 0.5 mg/kg) was ameliorative. Data demonstrate that steroidogenesis is altered by HIV-1 Tat
or morphine and that physiological AlloP attenuates resulting neurotoxic and psychomotor effects.
1. Introduction
Drugs of abuse interact with human immunodeficiency virus type 1
(HIV-1) proteins to promote central nervous system (CNS) dysfunction
and/or toxicity in cultured neural cells or animal models (Cai et al.,
2016; Mediouni et al., 2015a, 2015b; Nath et al., 2002; Silverstein
et al., 2012; Soontornniyomkij et al., 2016). In particular, the HIV-1
regulatory protein, trans-activator of transcription (Tat), promotes
neuroinflammation via the activation of infected and uninfected mi-
croglia and astrocytes, indirectly contributing to neurotoxicity (Hauser
et al., 2006; Nath et al., 2002). Opioids such as morphine, heroin,
methadone, and buprenorphine can exacerbate Tat-mediated cytokine
production (Festa and Meucci, 2012; Fitting et al., 2014a; Hauser et al.,
2012; Nath et al., 2002). However, Tat is also directly neurotoxic via
multiple mechanisms including the activation of NMDA receptors,
voltage-gated L-type Ca2+ channels, and mitochondrial dysfunction,
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resulting in bioenergetic crisis and cell death (Chopard et al., 2018;
Eugenin et al., 2007; Haughey et al., 2001; Hategan et al., 2017; Krogh
et al., 2014; Lecoeur et al., 2012; Malik et al., 2011; Napier et al., 2014;
Spector et al., 2019). The influence of opioids on Tat's direct, neurotoxic
effects are not well-understood, but may involve mitochondrial-medi-
ated processes including steroidogenesis.
Despite treatment with combined antiretroviral therapeutics, a
considerable proportion of patients infected with HIV-1 present with
endocrine dysfunction. Approximately 25% of HIV+ patients experi-
ence dysfunction of the hypothalamic-pituitary-gonadal (HPG; e.g.,
hypogonadism) and/or hypothalamic-pituitary-adrenal (HPA) axes
(e.g., elevated basal corticosterone with adrenal insufficiency in re-
sponse to HPA activation; Chrousos and Zapanti, 2014; George and
Bhangoo, 2013; Gomes et al., 2017; Lachâtre et al., 2017; Mirza et al.,
2018; Wong et al., 2017). In the era of combined antiretroviral therapy,
HPG and HPA disruption typically involve dysfunction within the CNS,
rather than dysfunction at peripheral steroid sources such as the gonads
or adrenals (Bons et al., 2013; Chrousos and Zapanti, 2014; Freda and
Bilezikian, 1999; Rochira and Guaraldi, 2014; Mirza et al., 2018). In
support, others have found evidence of neurosteroidogenic dysregula-
tion in post-mortem HIV+ brain tissue, cultured human fetal neurons,
and the brains of cats infected with feline immunodeficiency virus
(Maingat et al., 2013). Maintaining HPG/HPA function may improve
neurological outcomes.
Restoration of physiological steroid content may ameliorate neu-
rological deficits caused by HIV-1 Tat and/or combined opioid ex-
posure. Estradiol or pregnane steroids [progesterone (PROG) or the 3α-
hydroxy/5α-reduced PROG metabolite, allopregnanolone (AlloP)]
rescue Tat-mediated neurotoxicity in vitro (Adams et al., 2010, 2012;
Kendall et al., 2005; Paris et al., 2016; Salahuddin et al., 2019; Wallace
et al., 2006). Moreover, transgenic expression of HIV-1 Tat in male or
female mice increases anxiety- and depression-like behavior in vivo
(McLaughlin et al., 2017; Paris et al., 2014d; Salahuddin et al., 2019).
In females, these effects coincide with Tat-mediated elevations in cir-
culating corticosterone and are exacerbated by exposure to the clini-
cally-used opioid, oxycodone (Salahuddin et al., 2019). Exogenous
PROG can ameliorate Tat-mediated anxiety-like effects in mice (Paris
et al., 2014c, 2016) and this appears to be dependent on metabolism to
AlloP (Paris et al., 2016). Thus, the PROG metabolite, AlloP, may confer
protection against the CNS-targeted effects of HIV-1 Tat, but additional
evidence is needed to confirm this and to assess its effects on Tat and
opioid interactions.
Given that mitochondrial function is both a target for HIV-1 Tat and
a rate-limiting step for neurosteroidogenesis to occur, we hypothesized
that conditional expression of an HIV-1 tat transgene in mice would
alter central and/or circulating steroid content and that morphine
would further influence these effects. We expected this to co-occur with
neuronal mitochondrial dysfunction and neuron cell death. Lastly, we
anticipated the pregnane steroid, AlloP (previously found to exert
neuroprotection in cell culture), would ameliorate Tat-mediated mi-
tochondrial dysfunction, cell death, and the potentiation of morphine's
behavioral effects.
2. Materials and methods
The use of mice in these studies was pre-approved by the
Institutional Animal Care and Use Committees at Virginia
Commonwealth University and the University of Mississippi. All ex-
periments were conducted in accordance with ethical guidelines de-
fined by the National Institutes of Health (NIH Publication No. 85-23).
2.1. Animals and housing
Steroid analysis and behavioral studies utilized adult male mice that
expressed (or did not express) a GFAP-driven, doxycycline-inducible,
HIV–1IIIB tat1-86 transgene (N = 355) as previously described (Bruce-
Keller et al., 2008). Tat(−) and Tat(+) mice were generated in the
vivaria at Virginia Commonwealth University (MCV campus; for steroid
analyses and glucocorticoid insensitivity assay) and at the University of
Mississippi (for behavioral analyses). Primary cell culture analyses
utilized offspring acquired from timed-mated, C57BL/6J females
(N = 10; obtained from the Jackson Laboratory, Bar Harbor, ME). All
mice were ~70 days of age at the time of testing, were housed 4–5/cage
(Tat-transgenic mice) or were singly-housed (timed-mated C57BL/6J
mice), and were maintained in a temperature- and humidity-controlled
room on a 12:12 h light/dark cycle with ad libitum access to food and
water.
2.2. Chemicals
2.2.1. Chemicals used in vitro
Cells were treated with vehicle or a saturating dose of morphine
(500 nM in ddH20; #M8777, Sigma-Aldrich, Saint Louis, MO), vehicle
or low-to-high AlloP (0.1, 1, 10, or 100 nM dissolved in DMSO and
diluted 1:10,000 in media; #P8887, Sigma-Aldrich), and vehicle or
HIV-1 Tat1-86 (100 nM diluted to concentration in ddH20; #1002-2,
ImmunoDx, Woburn, MA). AlloP dosing reflects a range of low-to-high
physiological concentrations that have been found to confer protection
from several neurodegenerative insults (Ardeshiri et al., 2006; Irwin
and Brinton, 2014; Irwin et al., 2015; Lockhart et al., 2002; Waters
et al., 1997). The concentration of Tat reflects one from a range that
elicits functional deficits in glia and neurons similar to those observed
in HIV infection (Kruman et al., 1998; Nath et al., 1999; Singh et al.,
2004; El-Hage et al., 2005, 2008; Perry et al., 2010). Splenocytes were
treated with lipopolysaccharide (LPS) O26:B6 (204 nM in PBS; #L3755,
Sigma-Aldrich) and vehicle or low-to-high corticosterone (0.005, 0.05,
0.1, 0.5, or 5 μM) dissolved in EtOH and diluted 1:25 in media
(#27840, Sigma-Aldrich). SH-SY5Y cells were differentiated via se-
quential exposure to retinoic acid (1.5 mg/ml dissolved in 95% EtOH
and protected from light; #R2625, Sigma-Aldrich) and BDNF (10 μg/ml
dissolved in DMEM/F12; #SRP3014, Sigma-Aldrich) as described
below.
2.2.2. Chemicals used in vivo
Mice were treated with vehicle (saline 0.9%) or morphine (30 mg/
kg, i.p.; #M8777, Sigma-Aldrich) as well as vehicle or AlloP (0.5 or
1 mg/kg, s.c., dissolved in EtOH and diluted 1:10 in oil; #P8887,
Sigma-Aldrich). To induce HIV-1 tat1-86 transgene expression (or not),
Tat(+) and Tat(−) control mice were placed on doxycycline chow
(6 g/kg; Dox Diet #2018, Harlan Laboratories, Madison, WI) for 4
weeks in order to assess changes in steroidogenesis. To assess the in-
fluence of Tat and morphine on glucocorticoid insensitivity, Tat trans-
gene expression was induced for 8 weeks by doxycycline chow, and
mice were administered saline or ramping doses of morphine
(10–40 mg/kg, s.c. BID; increasing by 10 mg/kg every 2 days). To as-
sess the combined influence of Tat and AlloP on morphine-mediated
psychomotor behavior, transgene expression was induced via injection
of doxycycline (30 mg/kg, i.p.; #14422, Cayman Chemical, Ann Arbor,
MI) for 5 days with an additional two days of doxycycline washout prior
to behavioral testing (to minimize any potential non-specific behavioral
effects of doxycycline). Systemic AlloP (0.5 or 1 mg/kg, s.c.) was con-
currently-administered for the full duration of the behavioral testing
paradigm (8 days in total). AlloP dosing fell within a range that is ex-
pected to produce physiological concentrations in the brain (Gabriel
et al., 2004) and has previously demonstrated stepwise, dose-dependent
changes on affective behavior (Reddy and Kulkarni, 1996). The chosen
morphine concentration is found to enhance AlloP in the rodent brain
and circulation when administered acutely (Concas et al., 2006; Porcu
et al., 2014).
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2.3. Cell culture
2.3.1. Differentiated human neuroblastoma cells (SH-SY5Y)
SH-SY5Y neuroblastoma cells were obtained from ATCC (#CRL-
2266, Manassas, VA). These cells were chosen to assess the direct
neurotoxic effects of HIV-1 Tat on neurons given that they (1) are de-
void of glial inputs (obviating Tat's indirect neurotoxic contributions
via glially-mediated neuroinflammation), (2) express the endocrine
enzymes/receptors and opioid receptors of interest (Grassi et al., 2013;
Melcangi et al., 1993; Saify and Saadat, 2016; Salahuddin et al., 2019;
Toll et al., 1997), and (3) have been used for similar work previously
(Cai and Cadet, 2008; Hong et al., 2004; Hu et al., 2012; Mastrantonio
et al., 2016; Sun et al., 2016; Zhu et al., 2009). Cells were seeded onto
96-well plates at a density of 5 × 103/well for assessment of mi-
tochondrial membrane potential or were seeded onto 24-well plates at a
density of 2.5 × 104/well for assessment of cell death. Prior to differ-
entiation, cells were maintained in growth media: 89.5% DMEM/F12
(#11320-033, Life Technologies, Carlsbad, CA), 10% heat-inactivated
fetal bovine serum (FBS; #SH30071.03, Thermo Scientific Hyclone,
Logan, UT), and 0.5% antibiotic/antimycotic mixture (#15240-062,
Life Technologies). One day after seeding, growth media was fully ex-
changed for differentiation media #1 which contained retinoic acid
diluted 1:500 in growth media. After 5 d in differentiation media #1,
media was fully exchanged for the serum-free differentiation media #2
consisting of BDNF diluted 1:200 in DMEM/F12 (supplemented only
with the 0.5% antibiotic/antimycotic mixture). Cells underwent ex-
perimental manipulation 3 d later. Throughout differentiation, media
was exchanged every 48 h. Differentiation with these factors promotes
cell cycle arrest, expression of mature neuron markers (including a shift
from nestin+ to microtubule-associated protein 2+ expression), and a
polarized morphology (Constantinescu et al., 2007; Encinas et al., 2000;
Murillo et al., 2017; Salahuddin et al., 2019; Shipley et al., 2016).
2.3.2. Primary C57BL/6J striatal neurons
Primary striatal medium spiny neuron cultures were prepared as
previously described (Kim et al., 2018; Zou et al., 2011). These cells
were utilized given prior work demonstrating the dorsal striatum to be
among the largest reservoirs of HIV among post-mortem patients (Nath,
2015) and for neurons within this region to be selectively vulnerable to
Tat-mediated disruption in mice (Schier et al., 2017). In brief, primary
neurons were derived from the striatum of E15-17 C57BL/6J mice.
Dissected striata were minced and incubated at 37 °C (5% CO2) for
30 min with trypsin (2.5 mg/ml; #T4799, Sigma-Aldrich) and DNase
(15 μg/ml; D5025, Sigma-Aldrich) in neurobasal media (#21103049;
Life Technologies), supplemented with B-27 (#12587010, Life Tech-
nologies), L-glutamine (9.5 mM; Life Technologies), glutamate (25 μM;
Sigma-Aldrich), and antibiotic/antimycotic mixture (Life Technolo-
gies). Cells were centrifuged, triturated, and twice filtered through a
70 μm pore nylon mesh (Greiner Bio-One) and seeded onto poly-L-ly-
sine (#P2636, Sigma Aldrich) coated 24-well plates (7.5 × 104/well)
for 7–8 days in supplemented neurobasal media before experimental
manipulation.
2.3.3. Primary Tat-transgenic mouse splenocytes
Primary splenocyte cultures were prepared as previously described
(Avitsur et al., 2001; Kinsey et al., 2007) and were used to assess the
ability of prolonged HIV-1 Tat and morphine to alter glucocorticoid-
induced inhibition of peripheral immune cell viability. Briefly, mice
were sacrificed 24 h after administration of the final dose of morphine
(or vehicle) and spleens were harvested. Tissues were passed through a
70 μm pore nylon mesh (Greiner Bio-One) with 10 mL of RPMI media
(#22400089, Life Technologies) to prepare a cell suspension. Cells were
lysed with a hypotonic salt solution (0.16 M NH4Cl, 10 mM KHCO3,
0.13 mM EDTA) and suspended in RPMI media (#22400089, Life
Technologies), supplemented with 10% heat-inactivated fetal bovine
serum (FBS; #SH30071.03, Thermo Scientific), 7.5% NaHCO3
(#25080094, Life Technologies), and antibiotic/antimycotic mixture
(Life Technologies), centrifuged, and filtered through a 70 μm pore
nylon mesh (Greiner Bio-One). Duplicate splenocyte samples were
seeded onto 96-well plates with corticosterone and stimulated with LPS
for 48 h.
2.4. Steroid profiling by gas chromatography-tandem mass spectrometry
(GC/MS/MS)
Brain and plasma steroid content was measured in Tat(−) and Tat
(+) male mice after one month on doxycycline following handling
(baseline), saline injection (0.9%, i.p., 60 min post-treatment), or
morphine injection (30 mg/kg, i.p., 60 min post-treatment).
2.4.1. Tissue preparation
Blood was collected in heparinized plastic tubes, centrifuged, and
plasma (26–168 μl) was collected and stored at −80 °C. Whole brains
were harvested, hemisected (mid-sagittally), weighed (141–256 mg),
frozen in liquid nitrogen, and stored at −80 °C.
2.4.2. GC/MS/MS
A panel of steroids was identified and quantified simultaneously in
individual tissues by GC/MS/MS as previously described (Liere et al.,
2000; Zhu et al., 2017). Briefly, steroids were first extracted from
hemisected whole brains and plasma with 10 vol of methanol (MeOH)
and the following internal standards were added to the extracts for
steroid quantification: 2 ng of 2H6-5α-dihydroprogesterone (DHP; CDN
Isotopes, Sainte Foy la Grande, France) for 5α/β-DHP, 2 ng of epie-
tiocholanolone for pregnenolone (PREG), 20α-dihydropregnenolone
(20α-DHPREG), 3α/β5α/β-tetrahydroprogesterone (THP), 5α20α-
THP, 3α/β5α/β20α-hexahydroprogesterone (HHP) and 3α/β5α/β-tet-
rahydrodeoxycorticosterone (THDOC), 2 ng of 13C3-progesterone (P)
for P, 2 ng of 19-norPROG for 20α-DHP, 16α-hydroxyprogesterone
(16α-OHP), 17α-hydroxyprogesterone (17αOHP), 5α/β-DHDOC (di-
hydrodeoxycorticosterone), 5 ng of 13C3-deoxycorticosterone (DOC) for
DOC, 10 ng of 2H8-corticosterone for corticosterone, 5α-dihy-
drocorticosterone (5α-DHB) and 3α/β5α/β-tetrahydrocorticosterone
(THB). Samples were purified and fractionated by solid-phase extrac-
tion with the recycling procedure (Liere et al., 2004). Briefly, the ex-
tracts were dissolved in 1 ml MeOH and applied to the C18 cartridge
(500 mg, 6 ml, International Sorbent Technology, IST), followed by
5 ml of MeOH/H2O (85/15, vol/vol). The flow-through, containing the
free steroids, was collected and dried. After a previous re-conditioning
of the same cartridge with 5 ml H2O, the dried samples were dissolved
in MeOH/H2O (2/8, vol/vol) and re-applied. The cartridge was then
washed with 5 ml H2O and 5 ml MeOH/H2O (1/1, vol/vol) and un-
conjugated steroids were eluted with 5 ml MeOH/H2O (9/1, vol/vol).
The fraction containing the unconjugated steroids was then filtered and
further purified and fractionated by high-performance liquid chroma-
tography (HPLC). The HPLC system is composed of a WPS-3000SL
analytical autosampler and a LPG-3400SD quaternary pump gradient
coupled with a SR-3000 fraction collector (Thermo Scientific). The
HPLC separation was achieved with a Lichrosorb Diol column (25 cm,
4.6 mm, 5 μm) in a thermostated block at 30 °C. The column was
equilibrated in a solvent system of 90% heptane and 10% of a mixture
composed of heptane/isopropanol (85/15, vol/vol). Elution was per-
formed at a flow-rate of 1 ml/min, first 90% heptane and 10% of
heptane/isopropanol (85/15, vol/vol) for 15 min, then with a linear
gradient to 100% acetone in 2 min. The column was washed with
acetone for 15 min. Two fractions were collected from the HPLC
system: 5α/β-DHP were eluted in the first HPLC fraction (3–15 min)
and was next silylated with 50 μl of a mixture N-methyl-N-tri-
methylsilyltrifluoroacetamide/ammonium iodide/dithioerythritol
(1000:2:5 vol/wt/wt) for 15 min at 70 °C. The second fraction
(15–29 min) containing PREG and its derivatives, P, DOC, corticos-
terone and their precursors and their reduced and hydroxylated
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metabolites were derivatized with 25 μl of HFBA and 25 μl of anhy-
drous acetone for 1 h at 20 °C. Both fractions were dried under a stream
of nitrogen and resuspended in heptane. GC/MS/MS analysis of the
biological extracts was performed using an AI 1310 autosampler, a
Trace 1310 gas chromatograph (GC), and a TSQ 8000 mass spectro-
meter (MS) (Thermo Scientific). Injection was performed in the splitless
mode at 250 °C (1 min of splitless time) and the temperature of the gas
chromatograph oven was initially maintained at 80 °C for 1 min and
ramped between 80 and 200 °C at 20 °C/min, then ramped to 300 °C at
5 °C/min and finally ramped to 350 °C at 30 °C/min. The helium carrier
gas flow was maintained constant at 1 ml/min during the analysis. The
transfer line and ionization chamber temperatures were 300 °C and
200 °C, respectively. Electron impact ionization was used for mass
spectrometry with ionization energy of 70 eV and GC/MS/MS analyses
were performed in multiple reaction monitoring (MRM) mode with
Argon as the collision gas. GC/MS/MS signals were evaluated using a
computer workstation by means of the software Excalibur®, release 3.0
(Thermo Scientific). Identification of steroids was supported by their
retention time and two or three transitions and quantification was
performed according to the more abundant transition with a previously
established calibration curve. The range of the limit of detection was
roughly 0.5–20 pg according to the steroid structure. The GC/MS/MS
analytical procedure was fully validated in terms of accuracy, re-
producibility and linearity in mouse brains (Liere et al., 2000; Zhu
et al., 2017). Concentrations of 5β-DHP, 5β-DHDOC, 3α,5β-THDOC,
and 3α,5β-THB were below the limit of quantification in all samples.
2.5. Splenocyte proliferation assay
Glucocorticoid insensitivity was assessed using a CellTiter
96®AQueous Non-Radioactive Cell Proliferation Assay kit (#G5421,
Promega, Madison, WI) per manufacturer instructions. Briefly, the
proliferation assay was performed 48 h after primary Tat(−) and Tat
(+) splenocytes were seeded on 96-well plates in duplicate and in-
cubated with LPS and corticosterone. Media was replaced with the
tetrazolium (MTS) and phenazine methosulfate (PMS) solution (1:20)
and incubated (37 °C; 5% CO2) for 4 h and read at 490 nm using a
PHERAstar FS microplate reader (BMG Labtech, Cary, NC). Viability of
each sample was expressed as the mean optical density (OD) of dupli-
cates. Corticosterone resistance was assessed by calculating the per-
centage of viable cells in each sample treated with a given dose of
corticosterone compared with the same sample treated with vehicle
[(OD of corticosterone treated sample/OD of non-treated sample) *
100].
2.6. Mitochondrial membrane potential (Δψm)
Mitochondrial membrane potential (Δψm) was assessed using a JC-
10 kit per manufacturer recommendations (#22800, AAT Bioquest,
Sunnyvale, CA). Briefly, JC-10 (a JC-1 analogue with improved H2O
solubility) reversibly forms aggregates when Δψm is maintained; when
depolarized, JC-10 falls into its monomeric state. Excited JC-10 ag-
gregates and monomers display distinct emission spectra allowing for a
ratiometric assessment of Δψm (ex/emaggregate: 490/590 nm; ex/
emmonomer: 490/525 nm). Experimental treatments were applied to
differentiated SH-SY5Y cells seeded on 96-well plates or primary,
striatal, medium spiny neurons seeded on 24 well plates and incubated
(37 °C; 5% CO2) for 30 min, followed by the addition of JC-10 and
another incubation (37 °C; 5% CO2) of 30 min in the dark. Fluorescence
was assessed in SH-SY5Y cells using a PHERAstar FS microplate reader
(BMG Labtech) at 5, 15, and 30 min later. Primary neurons were im-
aged 15 min later on a Zeiss Axio Observer Z1 microscope with Zeiss
Axiovision 4.8 software (Carl Zeiss). For both methods, each plate re-
presented one observation (n) in statistical analyses. 96-well plates had
four technical replicates per treatment group and 24-well plates had
two technical replicates. For imaging, fields within each well were
randomly chosen and at least 200 cells were counted per condition.
Δψm was calculated as the monomer:aggregate ratio (presented as
percent change from control values).
2.7. Live/dead assay
Neuron viability was assessed using a LIVE/DEAD® Viability/
Cytotoxicity Kit (#L-7013, Molecular Probes, Eugene, OR) per manu-
facturer instructions and as described (Salahuddin et al., 2019). Briefly,
experimental treatments were applied to primary medium spiny neu-
rons or SH-SY5Y cells seeded on 24-well plates and live/dead assay was
performed 20 h later. Prior work utilizing time-lapse microscopy
(0–60 h) identified the 20 h time-point as the earliest time when Tat-
and AlloP-treated cells significantly diverged on the measure of viabi-
lity (Paris et al., 2016). A working solution of DEAD Red (ethidium
homodimer-2; ex/em: 535/624 nm) and SYTO 10 (ex/em: 495/
520 nm) was prepared by diluting stocks in Hank's Balanced Salt So-
lution (HBSS; 1:500 dilution). Cell media was replaced with the DEAD
Red/SYTO 10 working solution and incubated (37 °C; 5% CO2) for
15 min in the dark. Cells were washed 3 times with HBSS, fixed with 4%
paraformaldehyde, and imaged as described for 24-well plates above.
Viability was assessed by calculating the proportion of necrotic cells [#
DEAD Red+ cells/# Total Cells) * 100].
2.8. Locomotor activity
Mice were acclimated to the testing room with 70 dB white noise for
30 min prior to drug administration. Mice were administered saline
(0.9%, i.p.) or morphine (30 mg/kg, i.p.) and, 30 min later, were al-
lowed to freely explore an open field apparatus
(40 cm × 40 cm × 40 cm; Stoelting Co., Wood Dale, IL) for 5 min.
Behavior was tracked and digitally-encoded via ANY-maze animal
tracking software (Stoelting Co.). Horizontal and vertical (i.e., rearing)
locomotor behaviors were assessed as indices of psychomotor activity
(Paris et al., 2016; Salahuddin et al., 2019).
2.9. Statistical analyses
All datasets were determined to be normally-distributed with equal
variance per Kolmogorov-Smirnov and subsequent Bartlett tests, re-
spectively. Steroid content for each analyte was assessed via separate
Student's t-tests (Fig. 1) or two-way ANOVAs (Fig. 2) with drug ma-
nipulation (saline or morphine) and genotype [(Tat(−) or Tat(+)] as
between-subjects factors. Mitochondrial membrane potential across
time in SH-SY5Y cells was assessed via repeated measures ANOVA with
treatment condition as the between-subjects factors and time as the
within-subjects factor. Glucocorticoid insensitivity assays were ana-
lyzed via three-way ANOVAs with drug condition (vehicle or mor-
phine), Tat condition (vehicle or Tat), and corticosterone concentration
as factors. Remaining analyses for Δψm, live/dead analyses, and beha-
vioral dependent measures were assessed via three-way ANOVAs with
drug condition (vehicle- or morphine-exposed), AlloP condition (ve-
hicle- or AlloP-exposed), and Tat condition (control or Tat-exposed) as
factors. Fisher's Protected Least Significant Difference post-hoc tests
determined group differences following main effects. Interactions were
delineated via simple main effects and main effect contrasts with alpha
controlled for multiple comparisons. For post-hoc contrasts, all possible
pairwise comparisons were made with the exception of repeated mea-
sures analyses conducted in Fig. 4B, wherein a priori planned contrasts
where performed between all groups and control- (hatched line) or Tat-
(red open circle) treatment groups following a significant interaction.
All analyses were considered significant when p < 0.05.
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3. Results
3.1. HIV-1 Tat alters central steroid biosynthesis
To first assess whether HIV-1 Tat influences pregnane steroidogen-
esis, central and circulating steroid levels were measured in Tat(−) and
Tat(+) male mice. The induction of HIV-1 Tat significantly altered
baseline steroid content in the brain (Fig. 1A–C), independent of any
effects on circulating steroid content (Fig. 1D–F). Compared to Tat(−)
controls, brains collected from Tat(+) mice had significantly greater
concentrations of the prohormone, pregnenolone (p = 0.03), as well as
the 5α-reduced progesterone metabolites, 3α,5α-THP (i.e., AlloP;
p = 0.003) and 3β,5α-THP (p = 0.02), and their respective 20α-re-
duced metabolites, 3α,5α,20α-HHP (p = 0.0003) and 3β,5α,20α-HHP
(p = 0.01; Fig. 1B). The glucocorticoid precursor, deoxycorticosterone
(DOC), was significantly reduced in Tat(+) brains compared to their
Tat(−) counterparts (p = 0.006; Fig. 1B). No additional baseline dif-
ferences were observed in pregnane steroid content within the brain
(Fig. 1A–C), nor were differences in plasma content of any steroid ob-
served (Fig. 1D–F). Baseline concentrations of 3α,5β,20α-HHP were too
low to depict in Fig. 1, but did not change [Tat
(−)Brain = 0.008 ± 0.001; Tat(+)Brain = 0.011 ± 0.004; Tat
(−)Plasma = 0.004 ± 0.001; Tat(+)Plasma = 0.005 ± 0.001]. Thus,
the induction of HIV-1 Tat was associated with increased content of
pregnenolone and progesterone's 5α-reduced metabolites, and de-
creased deoxycorticosterone in the brain (independent of changes in
plasma steroid concentrations).
3.2. Morphine increases central and peripheral steroid content
In order to assess the additive influence of morphine administration
on Tat-mediated steroid biosynthesis, central and circulating steroid
contents were measured in Tat(−) and Tat(+) male mice 60 min after
an acute injection of saline (0.9%, i.p.) or morphine (30 mg/kg, i.p.).
Irrespective of Tat exposure, acute morphine significantly increased
brain pregnane steroid biosynthesis, apparently activating the HPA
stress axis (Fig. 2A–C). Compared to saline-administration, morphine
significantly increased central progesterone (p < 0.0001), and its 20α-
or 5α-reduced metabolites including 20α-DHP (p = 0.0003), 5α-DHP
(p < 0.0001), AlloP (p < 0.0001), 3β,5α-THP (p < 0.0001),
3α,5α,20α-HHP (p < 0.0009), and 3β,5α,20α-HHP (p = 0.008;
Fig. 2A–C). Morphine significantly increased all corticosteroids ex-
amined in brain compared to saline-induced concentrations
(p < 0.0001–0.03; Fig. 2A–C) with the exception of 3α,5α-THB,
3α,5β-THB, 5β-DHDOC, and 3α,5β-THDOC which were below the
limits of detection in brain (Fig. 2B). 3α,5β,20α-HHP was also below
the limit of quantification in brain.
In plasma, acute morphine significantly increased concentrations of
progesterone (p = 0.008), its 5α-reduced metabolites, 5α-DHP
(p < 0.0001) and AlloP (p < 0.0001), as well as its 20α-reduced
metabolites including 20α-DHP (p = 0.0003) and 3α,5α,20α-HHP
(p < 0.0001). As observed in the brain, morphine significantly in-
creased circulating concentrations of all detectable corticosteroids
compared to saline-induced content (p < 0.0001–0.03; Fig. 2D–F)
with the exception of 3α,5α-THB which only tended to be increased
(p = 0.059, n.s.). Circulating pregnenolone and 20α-DHPREG did not
differ from saline administration. 3α,5β,20α-HHP was below the limit
of quantification in plasma. Thus, acute morphine administration
Fig. 1. Pregnane steroid content of HIV-1 Tat-transgenic mice [Tat(+)] and non-Tat-expressing controls [Tat(−)] (n = 8/group) was assessed in brain (heatmap in
panel A and raw concentrations in panel B) and plasma (heatmap in panel D and raw concentrations in panel E). Tat-mediated steroid changes in the brain are
summarized in panel C. Tat expression did not influence steroid content in plasma (see panel F). Black heatmap panels indicate BLQ steroids. * indicates a significant
difference between Tat(−) and Tat(+) mice (Student's t-test; p < 0.05). BLQ = below limit of quantification; DHB = dihydrocorticosterone;
DHDOC = dihydrodeoxycorticosterone; DHP = dihydroprogesterone; DHPREG = dihydropregnenolone; DOC = deoxycorticosterone;
HHP = hexahydroprogesterone; PREG = pregnenolone; PROG = progesterone; THB = tetrahydrocorticosterone; THDOC = tetrahydrodeoxycorticosterone;
THP = tetrahydroprogesterone.
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activated the HPA axis, increasing pregnane and corticosteroid contents
in brain and plasma.
3.3. Exposure to HIV-1 Tat, but not morphine, induces glucocorticoid
resistance
Alterations in central and circulating steroid expression prompted
further examination of the effects of HIV-1 Tat and morphine on per-
ipheral glucocorticoid activity. Splenocytes were harvested from Tat
(−) and Tat(+) mice after 2 weeks of ramping morphine or saline
exposure and incubated with LPS and corticosterone for 48 h. Cell
viability was used to assess the ability of corticosterone to suppress
mitogen-stimulated splenocyte proliferation and survival. An inhibition
of the ability of corticosterone to reduce splenocyte viability indicates
glucocorticoid resistance. HIV-1 Tat significantly interacted with cor-
ticosterone concentration such that a greater proportion of Tat(+)
splenocytes were resistant to 5 μM corticosterone-induced suppression
of proliferation compared to Tat(−) splenocytes [F(4,25) = 10.24,
p < 0.0001] (Fig. 3), indicating a resistance to the inhibitory effects of
corticosterone. Tat did not significantly interact with morphine to in-
fluence glucocorticoid resistance.
3.4. Physiological, but not high, AlloP concentrations rescue Tat/morphine-
dysregulated Δψm
Given that alterations in central and circulating steroid synthesis
were observed, we next assessed the influence of HIV-1 Tat and mor-
phine on mitochondria which are known targets for Tat-mediated
dysfunction and a rate-limiting source of steroidogenesis. We assessed
the influence of Tat (100 nM) and/or morphine (500 nM) on mi-
tochondrial membrane potential (Δψm) via JC-10 using differentiated
human neuroblastoma cells (SH-SY5Y) and primary, striatal, medium
spiny neurons obtained from C57BL/6J mice. Central elevations of 5α-
reduced progestogens, such as those seen here in response to Tat or
morphine, are observed in models of brain injury and are proposed to
underlie an endogenous mechanism of neural protection (Schumacher
Fig. 2. Pregnane steroid content of HIV-1 Tat-transgenic mice [Tat(+)] and non-Tat-expressing controls [Tat(−)] that were administered saline (0.9%, i.p.) or
morphine (30 mg/kg, i.p.; n = 8/group), was assessed in brain (heatmap in panel A and raw concentrations in panel B) and plasma (heatmap in panel D and raw
concentrations in panel E). Morphine-mediated steroid changes in the brain are summarized in panel C and changes in plasma are summarized in panel F. Black
heatmap panels indicate BLQ steroids. † indicates a significant difference between saline- and morphine-treated mice, irrespective of Tat expression (two-way
ANOVA; p < 0.05). BLQ = below limit of quantification; DHB = dihydrocorticosterone; DHDOC = dihydrodeoxycorticosterone; DHP = dihydroprogesterone;
DHPREG = dihydropregnenolone; DOC = deoxycorticosterone; HHP = hexahydroprogesterone; PREG = pregnenolone; PROG = progesterone;
THB = tetrahydrocorticosterone; THDOC = tetrahydrodeoxycorticosterone; THP = tetrahydroprogesterone.
Fig. 3. HIV-1 Tat-transgenic mice [Tat(+)] or their non-Tat-expressing coun-
terparts [Tat(−)] were treated with saline or ramping morphine (10–40 mg/kg,
s.c.) twice daily for 2 weeks and splenocytes were harvested and cultured
(n = 6/group). Corticosterone (0.005, 0.05, 0.1, 0.5, or 5 μM) mediated in-
hibition of LPS-stimulated proliferation was used as an index of glucocorticoid
resistance. * indicates a significant increase in Tat(+) splenocytes vs. Tat(−)
splenocytes with 5 μM corticosterone (three-way ANOVA; p < 0.05).
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et al., 2014; Zhu et al., 2017). As such, we further assessed the poten-
tially protective role that 5α-reduced pregnane steroids may play on
Δψm following a Tat/morphine challenge by pretreating cells with a
concentration-curve of AlloP (0–100 nM).
As respective positive and negative controls, cells were treated with
the mitochondrial uncoupler, FCCP (1 μM), or pyruvate (10 mM) prior
to vehicle or HIV-1 Tat exposure. As expected, FCCP caused significant
depolarization of Δψm in differentiated SH-SY5Y cells [F(6,24) = 7.79,
p = 0.0001] (Fig. 4A) or of C57BL/6J primary neurons [F
(2,12) = 4.63, p = 0.03] (Fig. 4C). In SH-SY5Y cells, this effect was
observed 15- or 30-min post-treatment and was not influenced by Tat
(significant at each timepoint; p < 0.0001) indicating the cells were
viable throughout the testing period. Adding pyruvate maintained Δψm
in SH-SY5Y cells (Fig. 4A) and primary neurons (Fig. 4C) following
acute exposure to Tat.
HIV-1 Tat, morphine, and/or AlloP exposure caused significant,
time-dependent alterations in Δψm [F(38,120) = 1.84, p = 0.007] in
differentiated SH-SY5Y cells (Fig. 4B). Compared to controls, HIV-1 Tat
significantly depolarized Δψm within 15- and 30-min following treat-
ment (p = 0.03–0.007; Fig. 4B). On its own, morphine significantly
hyperpolarized Δψm 30 min post-treatment and significantly differed
from Tat at every timepoint (p < 0.001–0.01; Fig. 4B). Morphine
prevented Tat-induced Δψm depolarization at all timepoints assessed
(p < 0.0001–0.004; Fig. 4B). At all but the highest concentration,
AlloP did not affect Δψm when administered alone (p < 0.0001–0.02).
The highest AlloP concentration (100 nM) significantly hyperpolarized
Δψm at 30 min post-treatment (p= 0.02; Fig. 4B). Any concentration of
AlloP reversed the effects of HIV-1 Tat (p < 0.0001–0.01). Un-
expectedly, morphine and AlloP interacted to dysregulate Δψm. In
combination with morphine, the lowest AlloP concentration (0.1 nM)
hyperpolarized Δψm (5 and 30 min post-treatment, p = 0.02–0.03),
whereas the highest AlloP concentration significantly depolarized Δψm
(30 min post-treatment, p= 0.02; Fig. 4B) consistent with an inhibition
of electron transfer due to Ca2+ dysregulation. When Tat was added to
combined morphine and AlloP, Δψm dysregulation was more rapid with
the highest concentration of AlloP significantly depolarizing Δψm by 15
and 30 min, compared to controls (p = 0.0009–0.02; Fig. 4B), in-
dicating a shift in mitochondrial function from an active to an inactive
state.
In C57BL/6J primary neurons, HIV-1 Tat significantly interacted
with AlloP to influence Δψm [F(2,36) = 6.17, p = 0.005] (Fig. 4D and
E). Tat significantly depolarized Δψm compared to controls (p= 0.009)
and pretreatment with AlloP (10 or 100 nM) significantly attenuated
this effect (p = 0.0003–0.002; Fig. 4D and E). AlloP also significantly
interacted with morphine [F(2,36) = 3.28, p < 0.05] such that AlloP
abolished Tat or morphine-mediated depolarization at 10 nM, but this
protection was lost when the highest AlloP concentration (100 nM) was
co-administered with morphine (p > 0.05; Fig. 4D and E). Morphine
Fig. 4. Mitochondrial membrane potential (Δψm) of differentiated human neuroblastoma cells (SH-SY5Y; A-B) or C57BL/6J primary striatal medium spiny neurons
(C-E; n = 4/group) depicted as a percent change from vehicle-treated control. (A) SH-SY5Y cells following positive (FCCP 1 μM) and negative (pyruvate 10 mM)
control manipulations (with or without Tat 100 nM) or (B) treatment with Tat and/or morphine (500 nM) in combination with allopregnanolone (AlloP; 0.1, 1, 10, or
100 nM). Cells were assessed 5, 15, or 30 min following treatment. (C) C57BL/6J medium spiny neurons following positive (FCCP) and negative (pyruvate + Tat)
control manipulations or (D,E) treatment with Tat and/or morphine in combination with AlloP (10, or 100 nM; bar indicates 50 μm). * indicates a significant
difference from vehicle control (dashed line in panel B or solid line in panel E); ∧ indicates a significant difference from Tat-treated cells at the respective timepoint
(open red circles in panel B or hatched bars in panel E); **indicates a significant difference from all other datapoints; (repeated-measures ANOVA in panels A,B;
Student's t-test in panel C; three-way ANOVA in panel E; p < 0.05). (For interpretation of the references to colour in this figure legend, the reader is referred to the
Web version of this article.)
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and Tat did not significantly interact on their own. As such, Tat's con-
tribution to the collapse of Δψm can be ameliorated by low-to-high
physiological concentrations of AlloP. Morphine did not appear to
contribute to Tat-mediated effects on Δψm among isolated medium
spiny neurons, but did interact with the highest concentration of AlloP
to promote mitochondrial membrane depolarization.
3.5. Physiological, but not high, AlloP rescues Tat-induced cell death
The capacity for AlloP to ameliorate Tat-mediated depolarization of
Δψm prompted further examination of AlloP's direct protective capacity
on long-term neuron viability. Cells were incubated with treatments for
20 h (a previously-established timepoint at which PROG or AlloP
ameliorated Tat-mediated cell death; Salahuddin et al., 2019; Paris
et al., 2016). The direct neurotoxic effects of Tat (i.e., in the absence of
glial contribution), the concentration-dependent protective effects of
AlloP, and their interactions with morphine were sought.
HIV-1 Tat significantly interacted with AlloP (10 or 100 nM) to
influence neurotoxicity in both differentiated SH-SY5Y cells [F
(2,33) = 9.38, p = 0.0006] (Fig. 5A and B) and C57BL/6J striatal
medium spiny neurons [F(2,50) = 6.81, p = 0.002] (Fig. 5C and D).
Tat significantly increased the proportion of necrotic cells compared to
controls in either SH-SY5Y cells (p < 0.0001; Fig. 5A-B) or medium
spiny neurons (p = 0.001; Fig. 5C-D) and AlloP (10 or 100 nM) sig-
nificantly attenuated these effects (p = 0.004–0.01, Fig. 5B;
p=0.001–0.007, Fig. 5D). However, AlloP interacted with morphine in
both SH-SY5Y cells [F(2,33) = 3.70, p = 0.04] and medium spiny
neurons [F(2,50) = 3.70, p = 0.03] such that AlloP-mediated protec-
tion was lost when the highest concentration (100 nM) was co-ad-
ministered with morphine (p > 0.05; Fig. 5B,D). Tat did not sig-
nificantly interact with morphine to influence neurotoxicity. Thus,
physiological AlloP ameliorated direct Tat-mediated neurotoxicity.
High AlloP concentrations, such as those attained in the male rodent
brain under stress, were neurotoxic in combination with a saturating
concentration of morphine.
3.6. HIV-1 Tat potentiates, and AlloP attenuates, morphine's psychomotor
effects
To assess the functional behavioral interactions between HIV-1 Tat,
opiates, and exogenous neurosteroid, Tat(+) mice were pretreated with
vehicle or AlloP (0.5 or 1.0 mg/kg/d for 8 days, s.c.) while Tat was
induced via doxycycline (30 mg/kg/d for 5 days, i.p.; allowing for 2
days of doxycycline-washout prior to the testing day). Multiple negative
controls were included. To address the potential non-specific effects of
doxycycline, some mice were administered saline (5 d, i.p.) as unin-
duced controls. To account for potential leaky transgene expression
which can be observed in rtTA-transgenic mice, Tat(−) controls were
commensurately treated using the high AlloP concentration (1.0 mg/
kg). On day 8, mice received an acute dose of vehicle or morphine
(30 mg/kg, i.p.) and were assessed for psychostimulated locomotion
30 min later (Fig. 6A).
Among Tat(+) mice, induction of HIV-1 Tat significantly interacted
with administration of morphine [F(1,155) = 6.17, p = 0.01] and
AlloP [F(2,155) = 3.25, p = 0.04] to influence horizontal locomotor
activity (Fig. 6B). Morphine administration significantly increased lo-
comotion in oil-administered controls (p < 0.0001–0.01; Fig. 6B).
Inducing Tat significantly potentiated morphine's psychomotor effects
compared to their uninduced counterparts (p < 0.0001). Pretreatment
with AlloP (0.5 mg/kg) partly attenuated Tat-induced potentiation of
morphine's locomotor effects (p = 0.02); however, this group still de-
monstrated greater motor behavior than did uninduced controls
(p = 0.047). AlloP (1.0 mg/kg) fully attenuated Tat-induced po-
tentiation of morphine's psychomotor effects, significantly differing
from Tat-induced mice (p = 0.0005; Fig. 6B). Among Tat(−) control
mice, morphine significantly increased locomotor behavior compared
to saline [F(1,108) = 19.10, p < 0.001], but no effects of doxycycline
or AlloP (1 mg/kg) were observed (Fig. 6D). Thus, Tat potentiated the
psychomotor effect of acute morphine and this was ameliorated by
exogenous AlloP (1 mg/kg).
Among Tat(+) mice, morphine and AlloP significantly interacted to
influence rearing behavior, irrespective of Tat induction, [F
(2,155) = 4.14, p = 0.02] (Fig. 6C). Following saline administration,
Fig. 5. Live/dead assay of differentiated human
neuroblastoma cells (SH-SY5Y; A-B; n = 3–5/group)
or C57BL/6J primary striatal medium spiny neurons
(C-D; n = 5–6/group) depicted as the proportion of
DEAD Red+ cells following treatment with vehicle,
morphine (500 nM), Tat (100 nM), and/or allo-
pregnanolone (AlloP; 10 or 100 nM; bar indicates
50 μm). White arrows indicate necrotic cells. * in-
dicates a significant difference from control; ∧ in-
dicates a significant difference from Tat-treated
cells; ‡ indicates a significant difference from
Vehicle/AlloP (100 nM) treatment group (three-way
ANOVA in panels B,D; p < 0.05). (For interpreta-
tion of the references to colour in this figure legend,
the reader is referred to the Web version of this ar-
ticle.)
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mice that were pretreated with AlloP (0.5 mg/kg) reared significantly
more than those pretreated with oil or AlloP (1.0 mg/kg;
p = 0.001–0.006). Morphine significantly reduced rearing behavior in
all Tat(+) groups (p < 0.0001). Tat(−) control mice also demon-
strated a significant depression in rearing behavior following morphine
administration, compared to that following saline [F(1,108) = 81.15,
p < 0.001] (Fig. 6E). No effects of doxycycline or AlloP (1 mg/kg)
were observed (Fig. 6E).
4. Discussion
The hypotheses that exposure to Tat and morphine would alter
central or circulating steroid synthesis, directly promote neuronal mi-
tochondrial dysfunction, and neuron cell death were partly upheld. Tat
and morphine exerted separate effects to elevate steroid content, with
Tat increasing central pregnenolone and 5α-reduced progestogens
(while decreasing deoxycorticosterone) independent of changes in
plasma. Morphine largely increased both central and circulating preg-
nane steroids, the glucocorticoid corticosterone, and their 5α-reduced
metabolites consistent with activation of the HPA stress axis. In cell
culture studies, Tat and morphine also exerted separate effects with Tat
promoting glucocorticoid insensitivity, depolarizing Δψm, and facil-
itating neuronal death, while morphine hyperpolarized Δψm and did
not alter cell viability on its own. However, Tat and morphine did in-
teract in vivo, with Tat potentiating the psychomotor effects of acute
morphine in mice. Consistent with this, Tat exposure has been observed
to potentiate acute or sensitized psychostimulant-induced locomotion
and reward-related behavior of rodents (Harrod et al., 2008; Kesby
et al., 2017; Mediouni et al., 2015a, 2015b; Paris et al., 2014a), as well
as acute opioid-induced locomotion and behavioral disinhibition
(Salahuddin et al., 2019). Notably, Tat's effects to potentiate psychos-
timulant-reward and opioid-mediated behavioral disinhibition could be
attenuated concomitant with cyclical elevations in circulating
hormones (Paris et al., 2014b; Salahuddin et al., 2019). The hypothesis
that physiological concentrations of AlloP could ameliorate Tat-medi-
ated neuronal insults and resulting changes in behavior was likewise
upheld. However, an intriguing interaction was observed between high-
concentration AlloP (100 nM) and morphine to depolarize Δψm and
promote cell death. No untoward interactions between AlloP and
morphine were observed in vivo; rather, AlloP (1.0 mg/kg) attenuated
Tat's capacity to potentiate the physiological effects of acute morphine.
These findings support the notion that central steroidogenesis is influ-
enced by HIV-1 Tat or morphine and exogenous AlloP may exert several
therapeutic benefits that are of interest for present and future work.
This study is the first to comprehensively profile central and cir-
culating pregnane steroids in an animal model of neuroHIV. In other
animal models of CNS insult, including ischemic stroke and traumatic
brain injury, increased neurosteroidogenesis is observed and may re-
flect a local adaptive neuroprotective response (Guennoun et al., 2015;
Liu et al., 2012; Schumacher et al., 2014; Zhu et al., 2017). In support,
the 18 kDa translocator protein, which mediates mitochondrial cho-
lesterol import for steroidogenesis, is highly expressed in microglia and
astrocytes and is markedly upregulated following CNS injury and
neuroinflammation (Rupprecht et al., 2010). Exogenous AlloP can im-
prove experimental outcomes, including reductions to infarct volume,
gliosis, cytokine upregulation, and improvements to post-recovery
cognitive performance (Djebaili et al., 2005; Melcangi and Panzica,
2014; Sayeed et al., 2009). In vitro, AlloP is neuroprotective against
hypoxic or excitotoxic insults (Frank and Sagratella, 2000). These ef-
fects are likely due in part to its pharmacodynamic profile as a potent
positive allosteric modulator of GABAA receptors [and direct agonist in
high concentration (Callachan et al., 1987)] and as an antagonist of L-
type Ca2+ channels (Earl and Tietz, 2011; Hu et al., 2007), readily
restoring tonic inhibition within neural networks. As such, AlloP's
protective effects against Tat may be partly due to its capacity to ra-
pidly reinstate excitatory/inhibitory tone.
Fig. 6. (A) HIV-1 Tat-transgenic mice
(n = 14–16/group) were treated with
vehicle or allopregnanolone (AlloP; 0.5
or 1.0 mg/kg, s.c.) for 8 days prior to
testing and concurrent vehicle or dox-
ycycline (30 mg/kg, i.p.) for 5 days
prior to testing (with a 2-day doxycy-
cline washout period prior to testing
day). (B,D) Horizontal and (C,E) ver-
tical (rearing) motor behavior were
assessed 30 min after an acute injection
of saline or morphine (30 mg/kg, i.p.)
in Tat(+) and Tat(−) mice. * indicates
a significant increase with Tat induc-
tion compared to respective uninduced
control; † indicates a significant differ-
ence with morphine compared to re-
spective saline-administered control; ∧
indicates a significant decrease com-
pared to morphine/oil/Tat-induced
mice; ‡ indicates a significant differ-
ence for saline/AlloP (0.5 mg/kg)-
treated mice compared to all other
groups (irrespective of Tat condition);
(three-way ANOVA in panels B,C;
p < 0.05).
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HIV-1 Tat and morphine independently altered steroidogenesis in
vivo. In addition to local neurosteroidogenesis, Tat may influence cen-
tral steroid biosynthesis via alterations in cholesterol homeostasis. RNA
deep sequencing reveals Tat-mediated dysregulation of genes encoding
for lipid and cholesterol homeostasis in rat hippocampal neurons
(Mohseni Ahooyi et al., 2018). Moreover, exposure to Tat significantly
increased free and total cholesterol and cholesteryl ester within cul-
tured rat neurons, the latter of which was further increased by co-ap-
plication of cocaine (Mohseni Ahooyi et al., 2018). Opposing effects for
Tat (with or without cocaine) to reduce intra- and extracellular cho-
lesterol in astrocytes have also been observed (Cotto et al., 2018),
supporting the notion of dynamic changes in central cholesterol bioa-
vailability following exposure to Tat and psychostimulants. Given that
Tat increased splenocyte glucocorticoid resistance, it is reasonable to
assume that the opioid-driven HPA response would be modified in an
opioid-dependent organism.
Opiates are also demonstrated to influence steroidogenesis in ro-
dents, albeit largely via HPA activation and with a bias towards
synthesis of 5α-reduced metabolites, which can differ among species,
throughout ontogeny, and depend on the nature and duration of opioid
exposure (Bunce et al., 2015; Donegan and Bancos, 2018; Taylor et al.,
1997). In support, acute or chronic morphine increases central and
systemic 5α-reduction and AlloP formation in rodents (Concas et al.,
2006; Porcu et al., 2014), effects that could be blocked by the 5α-re-
ductase inhibitor, finasteride (Moradi-Azani et al., 2011; Verdi and
Ahmadiani, 2007). While there are notable species-related differences
in opioid activation of the HPA axis (Al-Hashimi et al., 2013; Vuong
et al., 2010), morphine is observed to induce steroidogenesis in rodents
via peripheral sources, particularly the adrenals (Concas et al., 2006; El
Daly, 1996). Adrenally-derived corticosterone likely contributed to the
great increase presently observed in the brain. High central gluco-
corticoid content is associated with neuronal injury and death (de Kloet
et al., 2015; Sapolsky, 2015). The extent to which these effects may
translate to opioid-dependent patients is not known; however, opioid
dependence may reduce HPA responsivity and/or obviate diurnal
ACTH/cortisol rhythmicity in people (Facchinetti et al., 1984; Vuong
et al., 2010). Pharmacologically-inducing withdrawal in people can
produce rebound HPA activation, adding complexity (Culpepper-
Morgan et al., 1992, 1997; Kreek, 2007). When abused, the initially
pleasurable effects of opioids dissipate and their continued use is lar-
gely motivated by a desire to escape the aversive effects of addiction
(George et al., 2012; Koob, 2020; Koob and Kreek, 2007). Thus, while
Tat-mediated changes in steroidogenesis may involve dysregulation of
cholesterol homeostasis, interactions with opioid drugs of abuse may be
expected to influence steroid-sensitive behaviors and are likely to differ
with dependence vs. acute exposure.
HIV-1 Tat is known to disrupt mitochondrial function and main-
taining AlloP at physiological levels may ameliorate mitochondrial
deficits. Congruent with the current findings, Tat can depolarize mi-
tochondrial membranes, induce opening of the mitochondrial perme-
ability transition pore (mPTP), drive reactive oxygen species formation,
and reduce ATP [reviewed in (Fields and Ellis, 2019; Rozzi et al.,
2017)]. Conversely, AlloP or synthetic neurosteroid analogues maintain
Δψm, improve mitochondrial oxygen consumption rate and glycolysis,
reduce opening of the mPTP, and preserve ATP synthesis in response to
insult (Grimm et al., 2014; Lejri et al., 2017; Leśkiewicz et al., 2008a,b;
Sayeed et al., 2009; Waters et al., 1997). However, protective effects of
AlloP are not seen at high, pharmacological concentrations (Leśkiewicz
et al., 2008a,b; Sayeed et al., 2009). On its own, morphine hyperpo-
larized Δψm which is consistent with past observations in primary
mouse neurons (Fitting et al., 2014b) and with reduced mPTP opening
and Cyt-c release in rat heart tissue (Chen et al., 2016). Physiological
AlloP concentrations (e.g., 10 nM) may restore cellular and mitochon-
drial homeostasis. Thus, increased Tat-induced neurosteroidogenesis
may be part of an adaptative cerebroprotective response, perhaps via
the enhancement of AlloP concentrations in the 10 nM range that are
mito- and neuroprotective. On the contrary, the large increases of
corticosterone and AlloP (≂ 50 nM) that occur with morphine treatment
may contribute to mitochondrial and neuronal dysfunction.
The mito/neurotoxic interactions between morphine and high-
concentration AlloP (100 nM) are intriguing. In low-to-physiological
concentrations, AlloP mediates phasic inhibition via activation of sy-
naptic GABAA Cl− channels; at high concentrations, AlloP activates δ-
subunit-containing, extrasynaptic GABAA receptors mediating tonic or
continuing Cl− conductance [reviewed in (Reddy and Estes, 2016)]. In
response to an excitotoxin, such as Tat, increased phasic or tonic Cl−
influx may be beneficial, restoring ion homeostasis. However, mor-
phine-dependence is demonstrated to downregulate KCC2 in several
CNS cell types leading to increased intracellular Cl− concentrations
(Ferrini et al., 2013; Gagnon et al., 2013; Taylor et al., 2016), which
may promote Cl− efflux in response to a potent agonist, such as AlloP.
Moreover, AlloP exhibits high potency and is a particularly efficacious
positive allosteric modulator of δ-containing GABAA receptors (Carver
and Reddy, 2016). Under these circumstances, high or supra-physio-
logical AlloP and morphine may increase cell excitability. Whether
supra-physiological concentrations of AlloP would produce toxic in-
teractions with morphine in vivo is not known; however, benzodiaze-
pines represent another class of positive GABAA allosteric modulators
that can exacerbate respiratory depression and many of the pathophy-
siological effects of opioids seen clinically (Dowell et al., 2016; Jones
et al., 2012; White and Irvine, 1999). Future work will further in-
vestigate the influence of opioid dependence on AlloP-mediated Tat
protection.
It should be noted that toxic interactions between opioids and Tat
largely depend on glial μ-opioid receptors (Fitting et al., 2014b; Zou
et al., 2011) and interactions with chemokine receptors (Festa and
Meucci, 2012; Kim et al., 2018). The present findings utilized isolated
neuron cultures to assess the direct neurotoxic relationship that may
exist between HIV-1 Tat and morphine, as well as the potential for
AlloP rescue. However, AlloP is demonstrated to influence immune
responding, quiescing activated microglia (Ahmad et al., 2005; Müller
and Kerschbaum, 2006) and directly or indirectly downregulating cy-
tokine production (Ghezzi et al., 2000); immune factors that play a
critical role in the progression of HIV (Thaney and Kaul, 2018). It will
be important to parse the influence of neurotoxic bystander effects in
these systems in the future.
5. Conclusions
These findings demonstrate the capacity for HIV-1 Tat or morphine
to influence central and circulating pregnane steroidogenesis.
Administration of exogenous AlloP in physiological concentrations
ameliorates Tat-mediated mitochondrial dysfunction and neurotoxicity,
even in combination with morphine. In mice, Tat potentiates, and AlloP
reverses, morphine's psychomotor effects. Thus, adjunctive therapeutics
that can maintain or enhance pregnane steroidogenesis may be bene-
ficial for neuroHIV symptomology among opioid-using and opioid-
naïve populations.
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